Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 139

Similar articles for PubMed (Select 21135189)

1.

Clinical characteristics of bloodstream infections due to ampicillin-sulbactam-resistant, non-extended- spectrum-beta-lactamase-producing Escherichia coli and the role of TEM-1 hyperproduction.

Waltner-Toews RI, Paterson DL, Qureshi ZA, Sidjabat HE, Adams-Haduch JM, Shutt KA, Jones M, Tian GB, Pasculle AW, Doi Y.

Antimicrob Agents Chemother. 2011 Feb;55(2):495-501. doi: 10.1128/AAC.00797-10. Epub 2010 Dec 6.

2.

Re: Incidence and Management of Extended-Spectrum Beta-Lactamase and Quinolone-Resistant Escherichia coli Infections after Prostate Biopsy.

Schaeffer EM.

J Urol. 2015 Jul;194(1):136. doi: 10.1016/j.juro.2015.04.056. Epub 2015 Apr 17. No abstract available.

PMID:
26088230
3.

Neonatal Escherichia coli Bloodstream Infections: Clinical Outcomes and Impact of Initial Antibiotic Therapy.

Bergin SP, Thaden J, Ericson JE, Cross H, Messina J, Clark RH, Fowler VG Jr, Benjamin DK Jr, Hornik CP, Smith PB; Antibacterial Resistance Leadership Group.

Pediatr Infect Dis J. 2015 Jun 10. [Epub ahead of print]

PMID:
26065862
4.

Evolvability as a function of purifying selection in TEM-1 β-lactamase.

Stiffler MA, Hekstra DR, Ranganathan R.

Cell. 2015 Feb 26;160(5):882-92. doi: 10.1016/j.cell.2015.01.035.

PMID:
25723163
5.

Computer aided screening of potent inhibitor compounds against inhibitor resistant TEM β-lactamase mutants from traditional Chinese medicine.

Zhu Q, Yin Y, Liu H, Tian J.

Bioinformation. 2014 Dec 31;10(12):750-6. doi: 10.6026/97320630010750. eCollection 2014.

6.

Silver nanoparticle-embedded polymersome nanocarriers for the treatment of antibiotic-resistant infections.

Geilich BM, van de Ven AL, Singleton GL, Sepúlveda LJ, Sridhar S, Webster TJ.

Nanoscale. 2015 Feb 28;7(8):3511-9. doi: 10.1039/c4nr05823b.

PMID:
25628231
7.

Drug resistance profiles and clonality of sporadic Shigella sonnei isolates in Ankara, Turkey.

Kacmaz B, Unaldi O, Sultan N, Durmaz R.

Braz J Microbiol. 2014 Oct 9;45(3):845-9. eCollection 2014.

8.

Risk factors, outcome and impact of empirical antimicrobial treatment in extended-spectrum β-lactamase-producing Escherichia coli bacteraemia.

Van Aken S, Lund N, Ahl J, Odenholt I, Tham J.

Scand J Infect Dis. 2014 Nov;46(11):753-62. doi: 10.3109/00365548.2014.937454. Epub 2014 Sep 8.

PMID:
25195648
9.

Risk factors and clinical outcome of sulbactam nonsusceptibility in monomicrobial Acinetobacter nosocomialis bacteremia.

Lai HH, Liou BH, Chang YY, Kuo SC, Lee YT, Chen TL, Fung CP.

J Microbiol Immunol Infect. 2014 Jul 28. pii: S1684-1182(14)00115-7. doi: 10.1016/j.jmii.2014.06.004. [Epub ahead of print]

PMID:
25081987
10.

Risk factors for extended spectrum β-lactamase-producing Escherichia coli versus susceptible E. coli in surgical site infections among cancer patients in Mexico.

Montes CV, Vilar-Compte D, Velazquez C, Golzarri MF, Cornejo-Juarez P, Larson EL.

Surg Infect (Larchmt). 2014 Oct;15(5):627-34. doi: 10.1089/sur.2013.189. Epub 2014 Jun 5.

PMID:
24901894
11.

Inhibitor-resistant TEM- and OXA-1-producing Escherichia coli isolates resistant to amoxicillin-clavulanate are more clonal and possess lower virulence gene content than susceptible clinical isolates.

Oteo J, González-López JJ, Ortega A, Quintero-Zárate JN, Bou G, Cercenado E, Conejo MC, Martínez-Martínez L, Navarro F, Oliver A, Bartolomé RM, Campos J; Spanish Network for Research in Infectious Diseases (REIPI).

Antimicrob Agents Chemother. 2014 Jul;58(7):3874-81. doi: 10.1128/AAC.02738-13. Epub 2014 Apr 28.

12.

Genotypic and phenotypic characterization of invasive neonatal Escherichia coli clinical isolates.

Shakir SM, Goldbeck JM, Robison D, Eckerd AM, Chavez-Bueno S.

Am J Perinatol. 2014 Nov;31(11):975-82. doi: 10.1055/s-0034-1370341. Epub 2014 Feb 24.

PMID:
24566757
13.

Characterization of third-generation cephalosporin-resistant Escherichia coli from bloodstream infections in Denmark.

Hansen F, Olsen SS, Heltberg O, Justesen US, Fuglsang-Damgaard D, Knudsen JD, Hammerum AM.

Microb Drug Resist. 2014 Aug;20(4):316-24. doi: 10.1089/mdr.2013.0157. Epub 2014 Feb 11.

PMID:
24517383
14.

Characterization of CTX-M-14 and CTX-M-15 producing Escherichia coli strains causing neonatal sepsis.

Sáez-López E, Guiral E, López Y, Montero I, Bosch J, Vila J, Soto SM.

Microb Drug Resist. 2014 Aug;20(4):281-4. doi: 10.1089/mdr.2013.0190. Epub 2014 Jan 31.

PMID:
24484616
15.

A single nucleotide in the promoter region modulates the expression of the β-lactamase OXA-61 in Campylobacter jejuni.

Zeng X, Brown S, Gillespie B, Lin J.

J Antimicrob Chemother. 2014 May;69(5):1215-23. doi: 10.1093/jac/dkt515. Epub 2014 Jan 9.

16.

Interaction of Al(2)O(3) nanoparticles with Escherichia coli and their cell envelope biomolecules.

Ansari MA, Khan HM, Khan AA, Cameotra SS, Saquib Q, Musarrat J.

J Appl Microbiol. 2014 Apr;116(4):772-83. doi: 10.1111/jam.12423. Epub 2014 Jan 7.

PMID:
24354999
17.
18.

Multidrug-resistant Escherichia coli bacteremia.

Alhashash F, Weston V, Diggle M, McNally A.

Emerg Infect Dis. 2013 Oct;19(10):1699-701. doi: 10.3201/eid1910.130309. No abstract available.

19.

Reply to "Internet-based solutions for analysis of next-generation sequence data".

Sherry NL, Stinear TP, Howden BP.

J Clin Microbiol. 2013 Sep;51(9):3163. doi: 10.1128/JCM.01393-13. No abstract available.

20.

Internet-based solutions for analysis of next-generation sequence data.

Larsen MV.

J Clin Microbiol. 2013 Sep;51(9):3162. doi: 10.1128/JCM.01348-13. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk